WallStreetZenWallStreetZen

NASDAQ: NUVA
NUVASIVE INC Stock Forecast, Predictions & Price Target

Analyst price target for NUVA

Based on 3 analysts offering 12 month price targets for NUVASIVE INC.
Min Forecast
$60.00+8.77%
Avg Forecast
$63.00+14.21%
Max Forecast
$67.00+21.46%

Should I buy or sell NUVA stock?

Based on 3 analysts offering ratings for NUVASIVE INC.
Strong Buy
Strong Buy
1 analysts 33.33%
Buy
2 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

NUVA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Anonymous
Morgan Stanley
HoldMaintains$62.00+12.40%2022-05-06
Wells Fargo
Top 14%
87
Strong BuyMaintains$62.00+12.40%2022-05-05
Needham
Bottom 6%
6
BuyMaintains$67.00+21.46%2022-05-05
RBC Capital
Bottom 10%
10
BuyInitiates Coverage On$60.00+8.77%2021-12-10

1 of 1

Forecast return on equity

Is NUVA forecast to generate an efficient return?
Company
24.61%
Industry
26.86%
Market
30.81%
NUVA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NUVA forecast to generate an efficient return on assets?
Company
9.25%
Industry
14.03%
NUVA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NUVA earnings per share forecast

What is NUVA's earnings per share in the next 3 years based on estimates from 7 analysts?
Avg 1 year Forecast
$2.31
Avg 2 year Forecast
$2.59
Avg 3 year Forecast
$3.04

NUVA revenue forecast

What is NUVA's revenue in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$1.2B+5.62%
Avg 2 year Forecast
$1.3B+13.37%
Avg 3 year Forecast
$1.4B+21.04%
NUVA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NUVA revenue growth forecast

How is NUVA forecast to perform vs Medical Devices companies and vs the US market?
Company
6.58%
Industry
5.76%
Market
8.93%
NUVA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NUVA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NUVA vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
NUVA$55.16$63.00+14.21%Strong Buy
ITGR$77.09$104.50+35.56%Strong Buy
NARI$60.83$95.50+56.99%Strong Buy
CNMD$109.85$165.00+50.20%Strong Buy
LIVN$63.57$100.80+58.57%Strong Buy

NUVASIVE Stock Forecast FAQ

Is NUVASIVE Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: NUVA) stock is to Strong Buy NUVA stock.

Out of 3 analysts, 1 (33.33%) are recommending NUVA as a Strong Buy, 2 (66.67%) are recommending NUVA as a Buy, 0 (0%) are recommending NUVA as a Hold, 0 (0%) are recommending NUVA as a Sell, and 0 (0%) are recommending NUVA as a Strong Sell.

What is NUVA's earnings growth forecast for 2022-2024?

(NASDAQ: NUVA) NUVASIVE's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 24.04%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.77%.

NUVASIVE's earnings in 2022 is -$37,375,000.On average, 7 Wall Street analysts forecast NUVA's earnings for 2022 to be $120,214,779, with the lowest NUVA earnings forecast at $114,490,266, and the highest NUVA earnings forecast at $124,898,472. On average, 7 Wall Street analysts forecast NUVA's earnings for 2023 to be $134,786,268, with the lowest NUVA earnings forecast at $131,143,396, and the highest NUVA earnings forecast at $138,429,140.

In 2024, NUVA is forecast to generate $158,204,731 in earnings, with the lowest earnings forecast at $156,123,090 and the highest earnings forecast at $159,765,962.

What is NUVA's revenue growth forecast for 2022-2024?

(NASDAQ: NUVA) NUVASIVE's forecast annual revenue growth rate of 6.58% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 5.76%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.93%.

NUVASIVE's revenue in 2022 is $1,158,501,000.On average, 5 Wall Street analysts forecast NUVA's revenue for 2022 to be $63,680,734,934, with the lowest NUVA revenue forecast at $63,492,658,652, and the highest NUVA revenue forecast at $63,886,609,249. On average, 5 Wall Street analysts forecast NUVA's revenue for 2023 to be $68,351,001,048, with the lowest NUVA revenue forecast at $67,995,248,567, and the highest NUVA revenue forecast at $69,089,671,428.

In 2024, NUVA is forecast to generate $72,971,932,266 in revenue, with the lowest revenue forecast at $72,826,217,382 and the highest revenue forecast at $73,117,647,150.

What is NUVA's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: NUVA) forecast ROA is 9.25%, which is lower than the forecast US Medical Devices industry average of 14.03%.

What is NUVA's Price Target?

According to 3 Wall Street analysts that have issued a 1 year NUVA price target, the average NUVA price target is $63.00, with the highest NUVA stock price forecast at $67.00 and the lowest NUVA stock price forecast at $60.00.

On average, Wall Street analysts predict that NUVASIVE's share price could reach $63.00 by May 5, 2023. The average NUVASIVE stock price prediction forecasts a potential upside of 14.21% from the current NUVA share price of $55.16.

What is NUVA's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: NUVA) NUVASIVE's current Earnings Per Share (EPS) is -$0.73. On average, analysts forecast that NUVA's EPS will be $2.31 for 2022, with the lowest EPS forecast at $2.20, and the highest EPS forecast at $2.40. On average, analysts forecast that NUVA's EPS will be $2.59 for 2023, with the lowest EPS forecast at $2.52, and the highest EPS forecast at $2.66. In 2024, NUVA's EPS is forecast to hit $3.04 (min: $3.00, max: $3.07).

What is NUVA's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: NUVA) forecast ROE is 24.61%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.